• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
79,273.33 753.03
( 0.96%)
Global Indices
Nasdaq
49,464.98 -3.46
(-0.01%)
Dow Jones
7,130.75 -16.31
(-0.23%)
Hang Seng
59,361.39 536.50
(0.91%)
Nikkei 225
10,604.22 -63.41
(-0.59%)
Forex
USD-INR
92.58 -0.61
(-0.65%)
EUR-INR
108.87 -0.98
(-0.89%)
GBP-INR
125.07 -1.17
(-0.93%)
JPY-INR
0.58 0.00
(-0.45%)

EQUITY - MARKET SCREENER

Vilin Bio Med Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
78871
INE0L4V01013
17.34
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VILINBIO
246.67
56.43
EPS(TTM)
Face Value()
Div & Yield %
0.15
10
0
 

abate as industries ltd
Karur Vysya Bank reappoints B Ramesh Babu as MD & CEO
Jan 27,2026
His current term is scheduled to end on July 28, 2026.

The board has recommended his reappointment for a third term of two years, effective 29 July, 2026. The appointment will be subject to the approval of the Reserve Bank of India (RBI) and the shareholders of the bank.

Karur Vysya Bank provides services such as personal, corporate, and agricultural banking and services to NRIs and SMBs.

The bank reported a 39.1% jump in standalone net profit to Rs 689.96 crore on an 11.8% increase in total income to Rs 3,303.13 crore in Q3 FY26 over Q3 FY25.

Shares of Karur Vysya Bank rose 0.66% to end at Rs 265.35 on the BSE.